Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation

作者：Peng Chen, Xuejie Li, Ruonan Zhang, Shuiping Liu, Xiang Yu, Mingming Zhang, Xiaying Chen, Ting Pan, Lili Yan, Jiao Feng, Ting Duan, Da Wang, Bi Chen, Ting Jin, Wengang Wang, Liuxi Chen, Xingxing Huang, Wenzheng Zhang, Yitian Sun, Guohua Li, Lingpan Kong, Xiaohui Chen, Yongqiang Li, Zuyi Yang, Qin Zhang, Lvjia Zhuo, Xinbing Sui, Tian Xie · 发表于：Theranostics · 年份：2020 · DOI：10.7150/thno.44705 · 被引用次数：396 · 研究领域：Ferroptosis and cancer prognosis、Cancer, Lipids, and Metabolism、RNA modifications and cancer

: Our data for the first time suggest that the natural product β-elemene is a new ferroptosis inducer and combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant CRC cells by inducing ferroptosis and inhibiting EMT, which will hopefully provide a prospective strategy for CRC patients with RAS mutations.